Equities

Beijing Tongrentang Co Ltd

600085:SHH

Beijing Tongrentang Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)31.52
  • Today's Change-9.38 / -22.93%
  • Shares traded7.95m
  • 1 Year change-38.39%
  • Beta1.1193
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BEIJING TONGRENTANG CO., LTD is a China-based company principally engaged in the production and sales of traditional Chinese patent medicines. The Company’s main products consist of liuwei dihuang series, tongren dahuoluo series, tongren niuhuang qingxin series, angong niuhuang series and donkey-hide gelatin series. The Company distributes its products under the brand of Tongrentang. The Company is also involved in the operation of Tongrentang drug stores. The Company distributes its products in domestic market and to overseas markets.

  • Revenue in CNY (TTM)17.96bn
  • Net income in CNY1.63bn
  • Incorporated1997
  • Employees16.78k
  • Location
    Beijing Tongrentang Co LtdNo. 52 Dongxinglong StreetDongcheng DistrictBEIJING 100062ChinaCHN
  • Phone+86 1 067179780
  • Fax+86 1 067152230
  • Websitehttps://gf.tongrentang.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kangmei Pharmaceutical Co Ltd5.21bn255.55m33.27bn4.41k129.594.73--6.380.01850.01850.37660.50790.36261.452.551,182,457.001.80-17.602.77-32.2420.63-72.784.95-101.190.8398--0.0346--16.60-22.17103.81-22.83-53.51--
Humanwell Healthcare Group Co Ltd25.56bn1.96bn38.85bn17.68k19.642.17--1.521.211.2115.8710.950.69023.802.741,445,825.007.136.2013.1212.7245.5942.8210.339.841.2112.090.317118.879.795.65-14.07--8.25--
Beijing Tiantan Biological Products Corp5.23bn1.27bn43.56bn4.86k34.194.09--8.330.64440.64442.655.380.34710.8137198.921,076,946.0011.4711.7116.7516.5054.2349.3933.0527.713.31--0.004616.6721.5712.0625.9916.8529.6738.97
Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd76.39bn3.42bn44.37bn28.05k13.741.30--0.58082.112.1146.9922.280.99466.074.602,723,576.004.715.908.9312.4016.5518.704.745.561.15--0.31730.026.6812.322.253.3427.7512.05
Beijing Tongrentang Co Ltd17.96bn1.63bn56.09bn16.78k34.454.32--3.121.191.1913.099.460.59121.0811.141,070,467.007.888.2015.6316.1744.4846.5913.3313.331.58--0.176530.9316.194.6816.928.03-12.0113.97
Shanghai Fosun Pharmaceutical (Group)41.61bn2.11bn65.23bn40.37k34.621.54--1.570.78830.788315.5417.710.36822.865.101,030,748.002.444.314.187.0147.1050.716.6310.650.7221--0.375531.92-5.8110.69-36.04-2.5010.95-3.34
Sichuan Biokin Pharmaceutical Co Ltd5.85bn3.80bn80.56bn2.09k21.2018.99--13.789.489.4814.5810.581.401.8164.162,802,843.0090.79--138.20--95.33--64.99--2.89--0.2807---20.11---176.40------
Data as of Sep 13 2024. Currency figures normalised to Beijing Tongrentang Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

11.63%Per cent of shares held by top holders
HolderShares% Held
Zhong Ou Asset Management Co., Ltdas of 30 Sep 202362.27m4.54%
Perseverance Asset Management LPas of 30 Sep 202331.50m2.30%
China Universal Asset Management Co., Ltd.as of 30 Sep 202314.46m1.05%
E Fund Management Co., Ltd.as of 30 Sep 202310.82m0.79%
Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 20249.65m0.70%
Harvest Fund Management Co., Ltd.as of 30 Jun 20247.97m0.58%
GF Fund Management Co., Ltd.as of 30 Jun 20247.70m0.56%
ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Sep 20236.00m0.44%
Minsheng Royal Fund Management Co., Ltd.as of 30 Jun 20244.74m0.35%
Yinhua Fund Management Co., Ltd.as of 30 Jun 20244.40m0.32%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.